New Three-Pronged attack tested for tough bone cancer recurrence
NCT ID NCT06492954
Summary
This early-stage study is testing the safety of a three-part treatment for osteosarcoma (a type of bone cancer) that has come back only in the lungs. The treatment combines a drug that helps the immune system fight cancer (atezolizumab), targeted radiation (SBRT), and surgery to remove the lung tumors. The goal is to see if this combination is safe and tolerable for patients who have few other options, as survival rates after the cancer returns are low.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chilldren's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.